{"id":305,"date":"2026-04-11T17:13:55","date_gmt":"2026-04-11T17:13:55","guid":{"rendered":"https:\/\/luciuspharmacy.com\/?post_type=product&p=305"},"modified":"2026-08-30T03:53:23","modified_gmt":"2026-08-30T03:53:23","slug":"lucitram-trametinib-2-mgx30-tablets","status":"publish","type":"product","link":"https:\/\/luciuspharmacy.com\/fr\/product\/lucitram-trametinib-2-mgx30-tablets\/","title":{"rendered":"LuciTram"},"content":{"rendered":"

HIGHLIGHTS OF PRESCRIBING INFORMATION <\/strong><\/span><\/p>\n

These highlights do not include all the information needed to use LuciTram safely and effectively. See full prescribing information for LuciTram.<\/strong><\/span><\/p>\n

 <\/span><\/p>\n

INDICATIONS AND USAGE<\/strong><\/strong><\/span><\/p>\n

LuciTram is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-na\u00efve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA approved test.<\/span><\/p>\n

LuciTram is indicated, in combination with dabrafenib, for: <\/span><\/p>\n

\u2022 the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. <\/span><\/p>\n

\u2022 the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. <\/span><\/p>\n

\u2022 the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.<\/span><\/p>\n

\u2022 the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options. <\/span><\/p>\n

\u2022 the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). <\/span><\/p>\n

\u2022 the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. <\/span><\/p>\n

 <\/span><\/p>\n

DOSAGE AND ADMINISTRATION<\/strong><\/strong><\/span><\/p>\n

The recommended dosage of LuciTram in adult patients is 2 mg orally once daily. The recommended dosage for LuciTram in pediatric patients is based on body weight. Take LuciTram at least 1 hour before or at least 2 hours after a meal.<\/span><\/p>\n

 <\/span><\/p>\n

DOSAGE FORMS AND STRENGTHS <\/strong><\/strong><\/span><\/p>\n

Tablets: 2 mg\u00d730 tablets<\/span><\/p>\n

 <\/span><\/p>\n

CONTRAINDICATIONS <\/strong><\/strong><\/span><\/p>\n

None.<\/span><\/p>\n

 <\/span><\/p>\n

WARNINGS AND PRECAUTIONS <\/strong><\/strong><\/span><\/p>\n

\u2022 New Primary Malignancies, Cutaneous and Non-Cutaneous: Can occur when LuciTram is used with dabrafenib. Monitor patients for new malignancies prior to, or while on therapy, and following discontinuation of treatment. <\/span><\/p>\n

\u2022 Hemorrhage: Major hemorrhagic events can occur. Monitor for signs and symptoms of bleeding. <\/span><\/p>\n

\u2022 Colitis and Gastrointestinal Perforation: Colitis and gastrointestinal perforation can occur in patients receiving LuciTram. <\/span><\/p>\n

\u2022 Venous Thromboembolic Events: Deep vein thrombosis (DVT) and pulmonary embolism (PE) can occur in patients receiving LuciTram. <\/span><\/p>\n

\u2022 Cardiomyopathy: Assess left ventricular ejection fraction (LVEF) before treatment, after one month of treatment, then every 2 to 3 months thereafter.  <\/span><\/p>\n

\u2022 Ocular Toxicities: Perform ophthalmological evaluation for any visual disturbances. For Retinal Vein Occlusion (RVO), permanently discontinue LuciTram. <\/span><\/p>\n

\u2022 Interstitial Lung Disease (ILD)\/Pneumonitis: Withhold LuciTram for new or progressive unexplained pulmonary symptoms. Permanently discontinue LuciTram for treatment-related ILD or pneumonitis. <\/span><\/p>\n

\u2022 Serious Febrile Reactions: Can occur when LuciTram is used with dabrafenib. <\/span><\/p>\n

\u2022 Serious Skin Toxicities: Monitor for skin toxicities and for secondary infections. Permanently discontinue LuciTram for intolerable Grade 2 or for Grade 3 or 4 rash not improving within 3 weeks despite interruption of LuciTram. Permanently discontinue for severe cutaneous adverse reactions (SCARs). <\/span><\/p>\n

\u2022 Hyperglycemia: Monitor serum glucose levels in patients with preexisting diabetes or hyperglycemia. <\/span><\/p>\n

\u2022 Hemophagocytic Lymphohistiocytosis (HLH): Interrupt treatment for suspected HLH. Discontinue treatment if HLH is confirmed. <\/span><\/p>\n

\u2022 Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of potential risk to a fetus and to use effective contraception. <\/span><\/p>\n

 <\/span><\/p>\n

ADVERSE REACTIONS <\/strong><\/strong><\/span><\/p>\n

Most common adverse reactions (\u2265 20%) for LuciTram as a single agent include rash, diarrhea, and lymphedema. <\/span><\/p>\n

Most common adverse reactions (\u2265 20%) for LuciTram in combination with dabrafenib include: <\/span><\/p>\n

\u2022 Unresectable or metastatic melanoma: pyrexia, nausea, rash, chills, diarrhea, vomiting, hypertension, and peripheral edema. <\/span><\/p>\n

\u2022 Adjuvant treatment of melanoma: pyrexia, fatigue, nausea, headache, rash, chills, diarrhea, vomiting, arthralgia, and myalgia. <\/span><\/p>\n

\u2022 NSCLC: pyrexia, fatigue, nausea, vomiting, diarrhea, dry skin, decreased appetite, edema, rash, chills, hemorrhage, cough, and dyspnea. <\/span><\/p>\n

\u2022 Adult patients with solid tumors: pyrexia, fatigue, nausea, rash, chills, headache, hemorrhage, cough, vomiting, constipation, diarrhea, myalgia, arthralgia, and edema. <\/span><\/p>\n

\u2022 Pediatric patients with solid tumors: pyrexia, rash, vomiting, fatigue, dry skin, cough, diarrhea, dermatitis acneiform, headache, abdominal pain, nausea, hemorrhage, constipation, and paronychia. <\/span><\/p>\n

\u2022 Pediatric patients with LGG: pyrexia, rash, headache, vomiting, musculoskeletal pain, fatigue, diarrhea, dry skin, nausea, hemorrhage, abdominal pain, and dermatitis acneiform. <\/span><\/p>\n

 <\/span><\/p>\n

USE IN SPECIFIC POPULATIONS <\/strong><\/strong><\/span><\/p>\n

\u2022 Lactation: Do not breastfeed.  <\/span><\/p>\n

\u2022 Females and Males of Reproductive Potential: May impair fertility. Counsel patients on pregnancy planning and prevention.<\/span><\/p>\n

 <\/span><\/p>\n

Storage <\/strong><\/strong><\/span><\/p>\n

Store at 20\u2103 to 25\u2103 (68\u2109 to 77\u2109), excursions permitted between 15\u2103 and 30\u2103 (59\u2109 and 86\u2109) [see USP Controlled Room Temperature]. Protect from moisture. <\/span><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

LuciTram is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-na\u00efve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA approved test.<\/p>","protected":false},"featured_media":2006,"comment_status":"open","ping_status":"closed","template":"","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"jetpack_seo_schema_type":""},"product_brand":[],"product_cat":[55],"product_tag":[],"class_list":["post-305","product","type-product","status-publish","has-post-thumbnail","product_cat-melanoma","first","instock","shipping-taxable","purchasable","product-type-simple"],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/product\/305","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/comments?post=305"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/media\/2006"}],"wp:attachment":[{"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/media?parent=305"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/product_brand?post=305"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/product_cat?post=305"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/product_tag?post=305"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}